• Disclosures of Relevant Financial Relationships
    It is the policy of AcademicCME that all faculty, instructors, and planners disclose relevant financial relationships with ineligible companies. Planners have no relevant financial relationships with ineligible companies to disclose related to this activity. Faculty have disclosed the following relevant financial relationships. All relevant financial relationships have been mitigated.

    Faculty Relationship Identified With:
    Jonathan Barratt, PhD,
    FRCP

    Research Grants: argenx; Calliditas Therapeutics; Chinook Therapeutics; Galapagos NV; GSK, Novartis; Travere Therapeutics
    Medical/Scientific Advisor: Alnylam
    Pharmaceuticals; argenx; Astellas Pharma; BioCryst Pharmaceuticals; Calliditas Therapeutics; Chinook Therapeutics; Dimerix; Galapagos NV; Novartis; Omeros; Travere Therapeutics; UCB; Vera Therapeutics; Visterra

     

    Planners and Peer Reviewers
    Timothy Hayes, MD, PhD; Charles V. Pollack Jr., MD; Kim Cheramie, MSN, RN-BC; Patrick Hayes and Chelsey Simonds hereby state that they do not have any relevant financial relationships to products or devices with any commercial interests related to the content of this activity.


    Accreditation Statement
    In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Credit Designation Statements
    AcademicCME designates this enduring material for a maximum of 0.50 AMA PRA
    Category 1 CreditsTM.
    AcademicCME designates this enduring material for a maximum of 0.50 CNE Contact
    Hours.
    AcademicCME designates this continuing education activity for 0.50 CPE Contact
    Hours (0.05 CEUs) of continuing pharmacy education credit (UAN JA4008190-0000-24-
    019-H01-P).
    Learners should only claim credit commensurate with the extent of their participation.


    This activity has been supported by an independent educational grant from Travere Therapeutics.

     

  • I am a:
  • If Physician, I am primarily a:
  • If Pharmacist, DOB:*
     - -
    2 digit month, 2 digit day, 4 digit year
  • I work primarily in:
  • I work primarily in the:
  • I engaged with this program via:
  • I would recommend this program and format to my colleagues.
  • I am aware of CE/CME courses available on Twitter from @ckd_ce.
  • 1. Which of the following is considered the primary goal in managing IgA nephropathy (IgAN)?*
  • 2. Which of the following biomarkers is often monitored to assess disease activity and progression in IgAN?*

  • Attestation to Time Spent on Activity:
    AcademicCME designates this activity for a maximum of 0.50 AMA PRA Category 1 CreditsTM, 0.50 CNE Contact Hours, or 0.50 CPE Contact Hours (0.05 CEUs) UAN # JA4008190-0000-24-019-H01-P for participation in the full educational activity.

  • I participated in this activity and claim:*
  • Date
     - -
    2 digit month, 2 digit day, 4 digit year
  • Should be Empty: